Protein associated with Alzheimer's disease linked to cognitive ability

August 14, 2017, CORDIS
Protein associated with Alzheimer’s disease linked to cognitive ability
Credit: Shutterstock

If the knowledge that our brains can produce new cells in adulthood is ever going to help in the fight against neurodegenerative disease, we need to understand the underlying mechanisms more effectively. Towards this end, a new study drawing on EU-funded research, sheds further light on the role the protein APP plays in neuroplasticity.

It is known that mutations in the gene responsible for the (APP) are implicated in the development of Alzheimer's Disease (AD). However, a new study recently published in the Journal of Alzheimer's Disease, and drawing on work from the EU-funded AGGRESSOTYPE project, has reported for the first time a link between these protein variants and childhood cognitive ability.

The study specifically observed an association between the APP gene and Performance IQ (PIQ). PIQ is believed to reflect fluid intelligence, referring to problem solving and reasoning abilities reliant on working memory, unlike so-called crystallised intelligence which denotes accumulated knowledge. The work raises questions about the protein's role in neuroplasticity and later cognitive disorders.

The role of neuroplasticity in cognitive health

Communication between cells in the brain occurs via synapses which contain
specialist proteins. Intellectual and cognitive function relies on this neural network retaining adaptability, known as neuroplasticity. However, mutations in some of these synaptic proteins can lead to brain dysfunctions and disorders, such as epilepsy or autism.

Researchers in this study focused specifically on a cluster of genes referred to collectively as the 'ARC complex' for their association with the Activity-regulated cytoskeleton associated protein (Arc). Arc and its regulators and inter-actors are known to facilitate neuroplasticity. However, the genes in the ARC complex have also been implicated in a number of conditions characterised by cognitive disabilities, most notably, Alzheimer's' Disease. The study was therefore predicated on the theory that the ARC complex may be an important determinant of cognitive abilities throughout the lifespan and also of age-related dementia.

To conduct the study, the researchers analysed both the IQ scores and genetic markers of 5,165 children from the Avon Longitudinal Study of Parents and Children. They then examined the DNA sequence variations of 17,008 adults with AD, alongside 37,154 healthy adults. They also considered the genetic data of 112,151 adults assessed on cognitive functions.

Tracking the pathways from molecules to behaviour

The study indeed found that a variation in the DNA sequence within the gene encoding the APP protein was associated with children's fluid intelligence. In adults, this same variation has been associated with AD. Additionally, the genetic variation within the APP gene appeared to be correlated with the efficiency of information processing (expressed as reaction time). It is known that APP encodes a that forms creates neuritic plaques or extracellular deposits in the grey matter of the brain, considered to be a pathological hallmark in AD brains. However, it is not known how these plaques affect brain functions and whether they themselves lead to AD.

The research team have described their work as 'exploratory' and called for follow-up studies to more accurately understand how APP variations may affect cognitive
function over a lifetime. It is hoped that this increased etiological understanding will eventually lead to treatment for cognitive dysfunctional disorders, such as AD.

The AGGRESSOTYPE (Aggression subtyping for improved insight and treatment innovation in psychiatric disorders) project which enabled some of the study's work, was set up to explore the biological basis of aggression, focusing specifically on childhood disorders, such as (ADHD). It takes a multidimensional approach, which includes inputs from genetics, brain imaging and epigenetics, as well as cognitive and behavioural assessments.

The project aims to develop algorithms for aggression prediction, accompanied by treatment options including not only pharmacological but also non-pharmacological strategies, such as biofeedback. It is estimated that aggressive psychiatric disorders affect more than 5 million children or adolescents in the EU and cost the health system more than six billion Euros per year to manage.

Explore further: A protein involved in Alzheimer's disease may also be implicated in cognitive abilities in children

More information: Project website: www.aggressotype.eu/

Related Stories

A protein involved in Alzheimer's disease may also be implicated in cognitive abilities in children

August 2, 2017
Rare mutations in the amyloid precursor protein (APP) have previously been shown to be strongly associated with Alzheimer's disease (AD). Common genetic variants in this protein may also be linked to intelligence (IQ) in ...

Overactive scavenger cells may cause neurodegeneration in Alzheimer's

June 30, 2017
For the first time, researchers from the University of Zurich demonstrate a surprising effect of microglia, the scavenger cells of the brain: If these cells lack the TDP-43 protein, they not only remove Alzheimer's plaques, ...

Genetic discovery provides new insight into cognitive disorders

January 17, 2017
An international team of scientists, led by Todd Lencz, PhD, professor at The Feinstein Institute for Medical Research at Northwell Health and Hofstra Northwell School of Medicine, have unlocked some of the genes responsible ...

Detecting Alzheimer's disease before symptoms emerge

May 31, 2017
Long before symptoms of Alzheimer's disease become apparent to patients and their families, biological changes are occurring within the brain. Amyloid plaques, which are clusters of protein fragments, along with tangles of ...

Alzheimer's gene associated with failure to adapt to cognitive challenge in healthy adults

June 26, 2017
Healthy adults carrying the gene APOE4—the strongest known genetic risk factor for Alzheimer's disease (AD)—may struggle to adapt their brain activity to increasing cognitive demands as they get older, according to a ...

More amyloid in the brain, more cognitive decline

June 14, 2017
A new study from the Center for Vital Longevity at The University of Texas at Dallas has found that the amount of amyloid plaques in a person's brain predicts the rate at which his or her cognition will decline in the next ...

Recommended for you

Researchers classify Alzheimer's patients in six subgroups

December 5, 2018
Researchers studying Alzheimer's disease have created an approach to classify patients with Alzheimer's disease, a finding that may open the door for personalized treatments.

Neuroscientists pinpoint genes tied to dementia

December 3, 2018
A UCLA-led research team has identified genetic processes involved in the neurodegeneration that occurs in dementia—an important step on the path toward developing therapies that could slow or halt the course of the disease. ...

Detecting signs of neurodegeneration earlier and more accurately

November 30, 2018
Signs of neurodegenerative diseases, appearing years before the emergence of clinical manifestations, can be detected during the examination of medical samples by means of fluorescence microscopy by using new sensitive and ...

Never-before-seen DNA recombination in the brain linked to Alzheimer's disease

November 21, 2018
Scientists from Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified gene recombination in neurons that produces thousands of new gene variants within Alzheimer's disease brains. The study, published today ...

New information on the pathological mechanisms of Alzheimer's disease

November 21, 2018
Researchers at the University of Helsinki have discovered a mechanism by which harmful tau protein aggregates are transmitted between neurons. Alongside amyloid plaques, tau aggregates in the brain are a significant factor ...

DNA vaccine reduces both toxic proteins linked to Alzheimer's

November 20, 2018
A DNA vaccine tested in mice reduces accumulation of both types of toxic proteins associated with Alzheimer's disease, according to research that scientists say may pave the way to a clinical trial.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.